Qiagen N.v. · NYSE:QGEN
Qiagen — Deutsche Bank German Swiss and Austrian Conference 2023
34 slides from Qiagen's conference presentation, Jun 29, 2023
Slide 1: Making improvements in life possible
Making improvements in life possible Investor Introduction May 2023
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. S
Slide 3: We help advance science and improve outcomes
We help advance science and improve outcomes Our Mission Enabling access to valuable insights from molecular research to clinical healthcare Our Vision Making improvements in life possible Q2 2023 Investor Introduction 3
Slide 4: QIAGEN at a glance
QIAGEN at a glance A global company with scale ~45% Americas $2.1 billion (2022 sales) Sales ~35% EMEA ~20% Asia-Pacific / Japan Highly recurring revenues Balanced customer markets ~6,200 employees known as QIAGENers ~ 88% 12% ~ ~ 50% 50% ~ Consumables and related revenues Instruments Molecular Diag
Slide 5: QIAGEN solutions are used across the world
QIAGEN solutions are used across the world by researchers - from young scientists to Nobel laureates - and clinical testing labs Q2 2023 Investor Introduction 5
Slide 6: More than 3 billion samples have been processed
More than 3 billion samples have been processed using QIAGEN sample preparation kits Dr. Darren Chooneea Research Scientist, London Natural History Museum Uses QIAGEN’s PowerSoil Pro Kit to explore the evolution of microorganisms as they adapted to changing environmental conditions and identify the
Slide 7: QIAGEN's innovative instrument portfolio
QIAGEN’s innovative instrument portfolio tackles a variety of molecular applications Dr. Johanna Andersson-Assarsson University of Gothenburg Uses QIAGEN’s QIAcuity digital PCR platform to identify gene variations that could help in the development of new therapies Q2 2023 Investor Introduction 7
Slide 8: QIAGEN's latent TB test
More than 100 million patients have been screened with QIAGEN’s latent TB test Dr. Kiyoyasu Fukushima Japan Red Cross Nagasaki Genbaku Isahaya Hospital Employs QuantiFERON TB Plus for latent tuberculosis detection to ultimately reduce Japan‘s high infection rate Q2 2023 Investor Introduction 8
Slide 9: QIAGEN is developing companion diagnostics
QIAGEN is developing companion diagnostics with over 30 Pharma companies Dr. Philippe Taniere Consultant histopathologist Queen Elizabeth Hospital Birmingham Relies on QIAGEN’s standardized, regulatory-approved tests to break the cellular code of cancer and find the right treatment for each patient
Slide 10: With QIAGEN's NGS kits
More than 4 million samples have been processed with QIAGEN’s NGS kits Asha Palat and Brandon Mistretta University of Houston’s Department of Biology and Biochemistry Use QIAGEN’s QIAseq FastSelect RNA Removal Kits with next-generation sequencing (NGS) to develop more effective and more humane cance
Slide 11: Every 10 seconds a crime scene sample is analyzed
Every 10 seconds a crime scene sample is analyzed with QIAGEN kits Rachel Oefelein Chief Scientific Officer at DNA Labs International Helping to bring closure to victims and their families by using QIAGEN’s forensic genetic genealogy tools to enable identification of assailants by matching genetic r
Slide 12: QIAGEN products are known for the highest quality
QIAGEN products are known for the highest quality Investing ~9-10% of sales in R&D and best-in-class manufacturing Q2 2023 Investor Introduction 12
Slide 13: Providing Sample to Insight solutions to uncover molecular insights
Providing Sample to Insight solutions to uncover molecular insights Sample technologies Assay technologies Discovery research Advancing understanding of life Pharma Faster and better drug R&D Clinical diagnostics Sample to Insight solutions Accurate disease diagnosis Automation systems Bioinformatic
Slide 14: Life sciences: Working to enable scientific advancements
Life sciences: Working to enable scientific advancements QIAGEN value Academic research 2022 sales ~$1 billion Pharma development Recognized innovator supporting scientific breakthroughs Able to translate innovations Applied testing into commercial products ~$5 billion addressable market Selected QI
Slide 15: Molecular Diagnostics: Helping to improve outcomes in healthcare
Molecular Diagnostics: Helping to improve outcomes in healthcare QIAGEN value Immune response 2022 sales ~$1.1 billion Infectious diseases Addressing testing areas with high or growing demand Strong automation portfolio Oncology with multi-year assay menu expansion underway ~$6 billion addressable m
Slide 16: Our Strategy: Leveraging a strong core portfolio to drive key pillars
Our Strategy: Leveraging a strong core portfolio to drive key pillars Expanding on solid leadership Early commercialization phases with strong growth potential Sample QuantiFERON QIAstat-Dx NeuMoDx QIAcuity technologies Leading immune Syndromic testing with Differentiated microfluidic Novel micropla
Slide 17: Sample Technologies: Building on solid leadership
Sample Technologies: Building on solid leadership Most comprehensive portfolio Ongoing automation upgrade program >300 consumables kits and range of automation systems >20,000 instrument placements in the market QIAcube Connect Tissue Stool Upgrade launched 2021 Cells Saliva >14,000 cumulative place
Slide 18: QuantiFERON TB: Best-in-class test for latent TB
QuantiFERON TB: Best-in-class test for latent TB Enabling hands-free processing of QFT-TB Gold Plus ~25-30% latent TB testing has been converted from skin test QFT-TB Gold Plus High performing Excellent Wide menu assay automation Embedded in QFT TB Gold Plus DiaSorin, DiaSorin menu • Can be fully au
Slide 19: QIAstat-Dx: Reliable and fast near-patient syndromic testing insights
QIAstat-Dx: Reliable and fast near-patient syndromic testing insights Unrivaled ease-of-use More than a “yes/no” No sample preparation answer for deeper QIAstat-Dx test menu CE-IVD FDA clinical insights Gastrointestinal Respiratory SARS CoV-2 1 2 3 4 Transfer Press Run Insert View results sample to
Slide 20: NeuMoDx: Driving a new generation of core lab integrated PCR testing
NeuMoDx: Driving a new generation of core lab integrated PCR testing >300 NeuMoDx CE-IVD test menu Offering the ease of clinical chemistry for cumulative molecular testing placements (1) HBV Blood-borne HCV viruses HIV CMV Easier Faster More versatile EBV 2.0 Simple three-step First results in ~1 ho
Slide 21: QIAcuity: Enabling wide access to digital PCR
QIAcuity: Enabling wide access to digital PCR Integrated instrument offering sample-in, result-out ease >1,300 cumulative placements (1) Scalable Easier Faster Greater Fully automated Over twice as fast flexibility workflow time-to-result QIAcuity One QIAcuity Four QIAcuity Eight Differentiated nano
Slide 22: We employ ~6,200 passionate QIAGENers
We employ ~6,200 passionate QIAGENers around the world from diverse backgrounds and locations Q2 2023 Investor Introduction 22
Slide 23: Strong global presence in developed and emerging markets
Strong global presence in developed and emerging markets Our global Direct sales in >30 and regional headquarters: Venlo Netherlands Germantown Global HQ countries Maryland Americas HQ Hilden Germany EMEA HQ Shanghai China HQ Shipping product to Singapore Asia-Pacific HQ >170 countries Q2 2023 Inves
Slide 24: Outlook: Q2 and FY 2023
Outlook: Q2 and FY 2023 Q2 2023 outlook FY 2023 outlook Net sales > $490 million CER > $2.05 billion CER Anticipated currency impact Neutral FX impact Neutral FX impact Double-digit CER growth in non-COVID product groups Adjusted EPS ≥ $0.50 CER ≥ $2.10 CER Anticipated currency impact Neutral FX imp
Slide 25: Maintaining financial flexibility with appropriate leverage
Maintaining financial flexibility with appropriate leverage Structure as of December 31, 2022 Maturities of debt instruments (In $ millions) $1.91 billion $1.42 billion Cash and short-term Convertible Bonds Schuldschein Convertible investments Bonds 117 2023 2024 2027 601 613 101 113 400 $492 millio
Slide 26: Capital allocation: Strong balance sheet to create greater value
Capital allocation: Strong balance sheet to create greater value Investing in growth Healthy cash flow and leverage ratio trends $ Expanding test menus and millions manufacturing capacity, 800 1.6x especially in the five pillars 700 1.5x 1.4x 600 Enhance value with M&A 500 Ongoing disciplined approa
Slide 27: Why invest: Well-diversified business spanning attractive markets
Why invest: Well-diversified business spanning attractive markets Diversified Broad Highly customer base geographic reach recurring revenues Well-balanced leadership in ~6,200 QIAGENers ensuring Growing installed base Life Sciences and access to attractive markets with generating demand for Molecula
Slide 28: Q1 2023 results
cet J . eo ~ Q1 2023 results eocce
Slide 29: Q1 2023 summary: Solid non-COVID sales growth
Q1 2023 summary: Solid non-COVID sales growth Net $502 million CER (1) sales +12% CER non-COVID Exceeded outlook for net sales and adjusted EPS vs outlook of ≥ $490 m CER Driven by +12% CER growth in non-COVID product groups Adjusted $0.52 CER (2) Teams executing on our strategy EPS Solid non-COVID
Slide 30: Q1 2023: +12% CER growth in non-COVID product groups
Q1 2023: +12% CER growth in non-COVID product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) -23% -23% (-20% CER) (-20% CER) $628 $628 $485 $485 265 Non-COVID 400 Sample product groups 173 technologies -32% CER +12% CER 434 174 Diagnos
Slide 31: Q1 2023: Five Pillars of Growth driving non-COVID sales gains
Q1 2023: Five Pillars of Growth driving non-COVID sales gains Sample technologies • Double-digit CER growth in non-COVID sales QuantiFERON • 19% CER sales growth with solid sales across all regions QIAstat-Dx • Dynamic sales growth in gastrointestinal and meningitis panels >$685 m NeuMoDx • Growing
Slide 32: Q1 2023: Americas and EMEA lead among regions
Q1 2023: Americas and EMEA lead among regions Americas • U.S., Mexico and Brazil: Double-digit non-COVID CER EMEA sales growth $155 m Americas +10% CER non-COVID $247 m Europe / Middle East / Africa +18% CER non-COVID Q1 2023 • Germany, United Kingdom, France and Italy: Top Net sales performances in
Slide 33: Q1 2023: Investing in the business to deliver sustainable growth
Q1 2023: Investing in the business to deliver sustainable growth Adj. operating income Adj. EPS Operating cash flow (In $ millions) (In $ per share) (In $ millions) Targeted investments into key drivers High level of R&D investments into menu expansion for key platforms $232 $207 $0.80 Digitizing QI
Slide 34: Your contacts
Your contacts Phoebe Loh Senior Director Calendar Global Investor Relations Annual General Meeting June 2023 Phone: +49 2103 29 11457 Mobile: +49 152 018 11457 Q2 2023 results August 2023 E-mail: phoebe.loh@qiagen.com Q3 2023 results October 2023 Alexandra Koenig Share information Coordinator Invest
Qiagen — Deutsche Bank German Swiss and Austrian Conference 2023 on 6ix